Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

MeReC Bulletin - Angiotensin-II receptor antagonists

The National Prescribing Centre (NPC) has published a MeReC Bulletin (PDF) that reviews the evidence for the place in therapy for angiotensin-II receptor antagonists (A2RA).

This bulletin reviews the evidence for angiotensin converting enzyme inhibitors (ACEI), A2RAs and a combination of both agents. The strength of the evidence is then compared for indications including hypertension, heart failure, diabetes and chronic kidney disease.

The frequency of cough is also considered for both drug classes. Data from the ONTARGET study are used to produce a patient decision aid that summarises the small benefit of A2RAs in reduction of cough. The levels of prescribing of both drug classes in primary and secondary care settings and cost savings are projected based on an increased proportional use of ACEIs.

Action: Clinicians who prescribed ACEIs or A2RAs will find this bulletin useful and informative.

Share 'MeReC Bulletin - Angiotensin-II receptor antagonists' on Email Share 'MeReC Bulletin - Angiotensin-II receptor antagonists' on Delicious Share 'MeReC Bulletin - Angiotensin-II receptor antagonists' on Digg Share 'MeReC Bulletin - Angiotensin-II receptor antagonists' on Facebook Share 'MeReC Bulletin - Angiotensin-II receptor antagonists' on Google+ Share 'MeReC Bulletin - Angiotensin-II receptor antagonists' on reddit Share 'MeReC Bulletin - Angiotensin-II receptor antagonists' on StumbleUpon Share 'MeReC Bulletin - Angiotensin-II receptor antagonists' on Twitter

atomic-wealth

No Comments to “MeReC Bulletin - Angiotensin-II receptor antagonists”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,616 spam comments.

atomic-wealth
fond-illness
summer